Thomas Ciulla

Company: Ikarovec

Job title: President & Chief Executive Officer

Seminars:

Developing Dual-Acting Gene Therapy to Combat Geographic Atrophy & Prevent AMD Progression 1:30 pm

Engineering bi-functional IKAR-001 gene therapy to provide synergistic complement targeting, inflammation control, and neuroprotection for GA treatment Utilizing advanced preclinical models to validate therapeutic efficacy and establish proof-of-concept for dual-protein approach Outline the role of PEDF and sCD46 in wet-AMD to emphasis the effectiveness of IKAR-001 gene therapy technologyRead more

day: Conference Day Two

Mastering Gene Therapy Delivery Routes to Optimize Patient Outcomes & Clinical Success 9:00 am

Comparing subretinal, intravitreal, and suprachoroidal delivery approaches to determine the most effective route for specific gene therapy applications Demonstrating advanced surgical techniques through live operative footage to provide hands-on insights into precise subretinal gene therapy injection procedures Evaluating pros and cons of each delivery method to guide evidence-based decision-making for optimal therapeutic outcomesRead more

day: Conference Day One

Panel Discussion: Evaluating the Interplay between Capsid Design & Route of Administration to Maximise Efficacy and Mitigate Adverse Effects 10:00 am

Exploring innovative capsid engineering approaches to improve stability and reduce immunogenicity for safer delivery Comparing administration routes and their impact on biodistribution to minimize patient risk while maintaining efficacy Integrating capsid properties with delivery strategies to achieve controlled exposure and sustained therapeutic effectRead more

day: Conference Day One